148 related articles for article (PubMed ID: 31688390)
1. The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.
Tveito M; Smith RL; Høiseth G; Molden E
J Clin Psychopharmacol; 2019; 39(6):561-566. PubMed ID: 31688390
[TBL] [Abstract][Full Text] [Related]
2. Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients.
Tveito M; Smith RL; Molden E; Haslemo T; Refsum H; Hartberg C; Correll CU; Høiseth G
J Clin Psychopharmacol; 2018 Dec; 38(6):570-576. PubMed ID: 30300295
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment.
Schoretsanitis G; Haen E; Gründer G; Stegmann B; Schruers KR; Hiemke C; Lammertz SE; Paulzen M
J Clin Psychopharmacol; 2016 Dec; 36(6):554-561. PubMed ID: 27811552
[TBL] [Abstract][Full Text] [Related]
4. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
Spina E; D'Arrigo C; Santoro V; Muscatello MR; Pandolfo G; Zoccali R; Diaz FJ; de Leon J
Ther Drug Monit; 2009 Dec; 31(6):758-63. PubMed ID: 19865002
[TBL] [Abstract][Full Text] [Related]
5. Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking.
Haslemo T; Olsen K; Lunde H; Molden E
Ther Drug Monit; 2012 Oct; 34(5):512-7. PubMed ID: 22972535
[TBL] [Abstract][Full Text] [Related]
6. Comedication of Valproic Acid Is Associated With Increased Metabolism of Clozapine.
Hommers L; Scharl M; Hefner G; Hohner M; Fischer M; Pfuhlmann B; Deckert J; Unterecker S
J Clin Psychopharmacol; 2018 Jun; 38(3):188-192. PubMed ID: 29620699
[TBL] [Abstract][Full Text] [Related]
7. Reduction in N-Desmethylclozapine Level Is Determined by Daily Dose But Not Serum Concentration of Valproic Acid-Indications of a Presystemic Interaction Mechanism.
Smith RL; Kyllesø L; Haslemo T; Andreassen OA; Molden E
Ther Drug Monit; 2019 Aug; 41(4):503-508. PubMed ID: 31259880
[TBL] [Abstract][Full Text] [Related]
8. Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation.
Baldelli S; Mauri MC; Di Pace C; Paletta S; Reggiori A; Rovera C; Clementi E; Cattaneo D
J Clin Psychopharmacol; 2018 Aug; 38(4):365-369. PubMed ID: 29912794
[TBL] [Abstract][Full Text] [Related]
9. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
[TBL] [Abstract][Full Text] [Related]
10. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
11. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients.
Tveito M; Smith RL; Molden E; Høiseth G
Eur J Clin Pharmacol; 2021 Feb; 77(2):215-221. PubMed ID: 33000414
[TBL] [Abstract][Full Text] [Related]
12. A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors.
Deng SH; Wang ZZ; Lu HY; Li L; Hu JQ; Zhu XQ; Xie HS; Chen HZ; Zhang M; Ni XJ; Qiu C; Shang DW; Wen YG
Ther Drug Monit; 2020 Aug; 42(4):636-642. PubMed ID: 32039940
[TBL] [Abstract][Full Text] [Related]
13. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.
Yatham LN; Fallu A; Binder CE
Acta Psychiatr Scand Suppl; 2007; (434):50-6. PubMed ID: 17688463
[TBL] [Abstract][Full Text] [Related]
14. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri TJ; Mican LM; Rozea H; Barner JC
Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
[TBL] [Abstract][Full Text] [Related]
16. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Sun L; Yagoda S; Yao B; Graham C; von Moltke L
Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
[TBL] [Abstract][Full Text] [Related]
17. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
18. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
Meyer JM
CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
[TBL] [Abstract][Full Text] [Related]
19. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
Skogh E; Sjödin I; Josefsson M; Dahl ML
J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
[TBL] [Abstract][Full Text] [Related]
20. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.
Arnaiz JA; Rodrigues-Silva C; Mezquida G; Amoretti S; Cuesta MJ; Fraguas D; Lobo A; González-Pinto A; Díaz-Caneja MC; Corripio I; Vieta E; Baeza I; Mané A; García-Rizo C; Bioque M; Saiz J; Bernardo M; Mas S;
Psychopharmacology (Berl); 2021 Mar; 238(3):665-676. PubMed ID: 33230696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
